Affimed gets FDA fast track status for AFM24 for EGFR lung cancer
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
Affimed Announces Annual General Meeting of Shareholders
Affimed Announces Annual General Meeting of Shareholders
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript
Truist Financial Sticks to Its Buy Rating for Affimed (AFMD)
Promising Clinical Trials and Strategic Financial Management Affirm Buy Rating for Affimed
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.